DES MOINES, IA, United States, via ETELIGIS INC., 04/02/2015 – – RemSleep Holdings Inc. www.remsleepholdings.com (OTC Pink: BVIGD) (PINKSHEETS: BVIGD) (OTC Pink: BVIG) (PINKSHEETS: BVIG), announced today the successful merger with Kat Gold Holdings Corp, with RemSleep being the succeeding company. The Super 8-K detailing the transaction can be seen at www.sec.gov as well as company website.
Sleep apnea is a medical condition that causes a person to have periodic episodes of interrupted breathing during sleep. Obstructive sleep apnea (OSA) inhibits restorative sleep, carrying significant implications such as cognitive impairment, and even sudden cardiac death. Treatment of this affliction to date has created a $9 Billion market with industry estimates anticipating a $17.9 billion market by 2017. Treating this global epidemic is currently addressed by patients using Continuous Positive Airway Pressure (CPAP) machines and interfaces. Unfortunately current models continue to have issues that cause patients to give up on treatment. Patient noncompliance is a mounting concern for the medical community.
RemSleep Holdings flagship product is The DeltaWave interface. This interface does not disrupt normal breathing mechanics, is not claustrophobic, causes less work of breathing (WOB), minimizes or eliminates drying of the sinuses, uses less driving pressure, and allows users to feel safe and secure while sleeping. RemSleep is confident that DeltaWave’s unique design will benefit patients with a more compliant CPAP interface that provides improved breathing, ease of use, and encourages deep restful sleep.
Russell Bird, CEO comments, “Our goal at RemSleep is to achieve optimum compliance and comfort for CPAP patients who suffer from sleep apnea. Years of research and development have led to the revolutionary DeltaWave CPAP interface, a design that addresses the stubborn issues that continue to affect a patient’s ability to comply with treatment.”
RemSleep Holdings will now implement an aggressive marketing and distribution program of the DeltaWave to reach institutions and clientele in demand of sleep apnea products in North America and worldwide as we expand our manufacturing and distribution facilities.
About RemSleep Holdings, Inc.
RemSleep Holdings, Inc was founded to design and manufacture devices and products for the treatment of sleep apnea and other respiratory conditions. We have extensive knowledge and understanding of CPAP and the challenges of patient compliance. RemSleep Holdings, Inc has patented a new, innovative sleep apnea product that will meet multiple market needs and be able to reach and address a large percentage of the patient population non-compliance issues worldwide through the DeltaWave CPAP interface.
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). RemSleep Holdings, Inc. cautions that statements and assumptions made in this news release constitute forward-looking statements and make no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risk, uncertainties, and estimates made by management. Actual results could differ materially from current projections or implied results.
RemSleep, Inc. undertakes no obligation to revise these statements following the date of this news release.
RemSleep Holdings, Inc.
Russell Bird / CEO
SOURCE: RemSleep Holdings Inc.